13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • KEYNOTE -522

    Acronym: 

    Keynote -522

    ACTRN/NCT /ethics: 

    NCT03036488

    Scientific title: 

    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Breast
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2017-03-07
    Molecular Target Anticipated End Date 2025-03-14
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast
    Cancer Stage All stages
    Anticipated Start Date 2017-03-07
    Anticipated End Date 2025-03-14

    Trial Summary

    The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).

    Lay Summary

    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    Sponsor / Cooperative group

    Bristol-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Nimit Singhal Recruitment on Hold